Now live: Pro — the full 13F research suite for serious investorsSee pricing →
Lynx1 Capital Management LP

Q1 2026 · 13F-HR

Lynx1 Capital Management LPholdings as filed

Filed 2026-05-04 · accession 0001910456-26-000002

$632.7M
Reported value
23
Positions
2026-03-31
Period end
View analyzed profile →PRO

Holdings as filed

CUSIPTickerIssuerValue% port.SharesClassVoting
86150R107STOKSTOKE THERAPEUTICS INC$155.1M24.5%4,763,673CommonSHARED
G3855L106GHRSGH RESEARCH PLC$151.3M23.9%10,763,288CommonSHARED
230031106CGEMCULLINAN THERAPEUTICS INC$127.4M20.1%8,963,500CommonSHARED
00847X104AGIOAGIOS PHARMACEUTICALS INC$88.3M14.0%2,611,568CommonSHARED
24823R105DNLIDENALI THERAPEUTICS INC$36.1M5.71%1,880,303CommonSHARED
12529R107CCCCC4 THERAPEUTICS INC$18.4M2.91%6,998,902CommonSHARED
500946108KRROKORRO BIO INC$17.4M2.75%1,538,296CommonSHARED
89854M101TCRXTSCAN THERAPEUTICS INC$8.1M1.28%8,019,148CommonSHARED
98401F105XNCRXENCOR INC$6.5M1.02%536,398CommonSHARED
74019P207DTILPRECISION BIOSCIENCES INC$5.4M0.86%985,113CommonSHARED
702712209PASGPASSAGE BIO INC$4.9M0.77%623,704CommonSHARED
64136E102NEUPNEUPHORIA THERAPEUTICS INC$3.6M0.56%875,328CommonSHARED
29384C108TRDAENTRADA THERAPEUTICS INC$2.7M0.42%211,689CommonSHARED
156944100CGONCG ONCOLOGY INC$2.1M0.34%31,591CommonSHARED
N44445109IMTXIMMATICS N.V$2.1M0.34%216,973CommonSHARED
25056L103DSGNDESIGN THERAPEUTICS INC$1.3M0.20%119,516CommonSHARED
92941V308VYNEVYNE THERAPEUTICS INC$973,1480.15%1,628,700CommonSHARED
95075A107HOWLWEREWOLF THERAPEUTICS INC$547,6730.09%657,786CommonSHARED
451033708IBIOIBIO INC$129,3440.02%68,076CommonSHARED
097702203BOLTBOLT BIOTHERAPEUTICS INC$124,4320.02%30,800CommonSHARED
N71542109PRQRPROQR THRAPEUTICS N V$110,9470.02%68,486CommonSHARED
00091E109ABSIABSCI CORPORATION$63,7350.01%21,245CommonSHARED
68232V884TRAWTRAWS PHARMA INC$27,5930.00%15,078CommonSHARED

Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.